Remdesivir shows "limited benefit" during trial, so why did the FDA approve it?

(Natural News) Remdesivir, the wonder drug touted to treat the Wuhan coronavirus (COVID-19), showed a “limited benefit” in a large trial involving patients exhibiting moderate symptoms. Gilead Sciences released the initial findings of its phase 3 trial Tuesday, saying that remdesivir “improved clinical outcomes by several different measures,” in a statement. A phase 3 trial involves testing the drug...